[{"id":"31764096-6379-4314-a6a8-370698657726","acronym":"","url":"https://clinicaltrials.gov/study/NCT02226276","created_at":"2021-01-18T10:26:21.550Z","updated_at":"2025-02-25T14:14:41.067Z","phase":"","brief_title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02226276","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/07/2015","start_date":" 01/07/2015","primary_txt":" Primary completion: 12/07/2021","primary_completion_date":" 12/07/2021","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2025-02-18"},{"id":"7137bb56-9c9c-4ff1-bf66-4a2cdf70604f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620187","created_at":"2021-01-19T20:34:19.621Z","updated_at":"2025-02-25T14:07:59.706Z","phase":"Phase 2","brief_title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","source_id_and_acronym":"NCT04620187","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-18"},{"id":"137ec32f-5e52-4616-9b33-b322d2b339d9","acronym":"TAPISTRY","url":"https://clinicaltrials.gov/study/NCT04589845","created_at":"2021-04-08T16:52:35.237Z","updated_at":"2025-02-25T14:07:57.580Z","phase":"Phase 2","brief_title":"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","source_id_and_acronym":"NCT04589845 - TAPISTRY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 920","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 09/25/2032","primary_completion_date":" 09/25/2032","study_txt":" Completion: 09/25/2032","study_completion_date":" 09/25/2032","last_update_posted":"2025-02-17"},{"id":"b33b770e-2030-41f5-b3a0-0baa9951a5d5","acronym":"ProHer","url":"https://clinicaltrials.gov/study/NCT05415215","created_at":"2022-06-13T16:55:43.094Z","updated_at":"2025-02-25T12:28:50.312Z","phase":"Phase 3","brief_title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","source_id_and_acronym":"NCT05415215 - ProHer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 347","initiation":"Initiation: 07/05/2022","start_date":" 07/05/2022","primary_txt":" Primary completion: 11/20/2024","primary_completion_date":" 11/20/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-17"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"1330d05c-ce55-45d8-aef6-64434dd03682","acronym":"IL Believe","url":"https://clinicaltrials.gov/study/NCT05081609","created_at":"2021-10-18T12:53:10.136Z","updated_at":"2025-02-25T16:45:39.607Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","source_id_and_acronym":"NCT05081609 - IL Believe","lead_sponsor":"Ascendis Pharma Oncology Division A/S","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-02-05"},{"id":"9663b458-bf8e-4744-aded-694ba1c51e6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06348134","created_at":"2024-04-04T16:39:16.597Z","updated_at":"2025-02-25T13:56:14.439Z","phase":"Phase 2","brief_title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","source_id_and_acronym":"NCT06348134","lead_sponsor":"University of Chicago","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 07/01/2034","primary_completion_date":" 07/01/2034","study_txt":" Completion: 07/01/2036","study_completion_date":" 07/01/2036","last_update_posted":"2025-02-05"},{"id":"469b756a-3292-44ae-9f90-6b3df9f3a41a","acronym":"ATEMPT","url":"https://clinicaltrials.gov/study/NCT01853748","created_at":"2021-01-18T08:16:43.277Z","updated_at":"2025-02-25T16:58:34.490Z","phase":"Phase 2","brief_title":"T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)","source_id_and_acronym":"NCT01853748 - ATEMPT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 512","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 08/26/2019","primary_completion_date":" 08/26/2019","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"4e07ea78-21b2-4abe-9c7a-53c1c0d6fed9","acronym":"KAN-HER2 MRD","url":"https://clinicaltrials.gov/study/NCT05388149","created_at":"2022-05-24T12:54:32.375Z","updated_at":"2025-02-25T17:25:36.146Z","phase":"Phase 2","brief_title":"Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease","source_id_and_acronym":"NCT05388149 - KAN-HER2 MRD","lead_sponsor":"University Health Network, Toronto","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/06/2022","start_date":" 12/06/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-01-31"},{"id":"f83a311f-ecd2-4321-b840-6d97a51514d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03032107","created_at":"2021-01-17T18:02:54.137Z","updated_at":"2025-02-25T16:05:47.433Z","phase":"Phase 1","brief_title":"A Study Of Pembrolizumab In Combination With Trastuzumab-DM1","source_id_and_acronym":"NCT03032107","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 02/17/2017","start_date":" 02/17/2017","primary_txt":" Primary completion: 10/29/2020","primary_completion_date":" 10/29/2020","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2025-01-27"},{"id":"3321b9eb-4041-44b7-9b45-28169a5b88a3","acronym":"BRIDGET","url":"https://clinicaltrials.gov/study/NCT05323955","created_at":"2022-04-12T13:52:41.307Z","updated_at":"2025-02-25T12:28:44.690Z","phase":"Phase 2","brief_title":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib","source_id_and_acronym":"NCT05323955 - BRIDGET","lead_sponsor":"Carey Anders, M.D.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 03/23/2023","start_date":" 03/23/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-12-11"},{"id":"23bb9de1-3af9-4aa6-8cce-545836191b15","acronym":"IMpassion050","url":"https://clinicaltrials.gov/study/NCT03726879","created_at":"2021-01-18T18:15:43.055Z","updated_at":"2025-02-25T13:52:41.144Z","phase":"Phase 3","brief_title":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","source_id_and_acronym":"NCT03726879 - IMpassion050","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 454","initiation":"Initiation: 01/11/2019","start_date":" 01/11/2019","primary_txt":" Primary completion: 02/05/2021","primary_completion_date":" 02/05/2021","study_txt":" Completion: 08/24/2023","study_completion_date":" 08/24/2023","last_update_posted":"2024-11-05"},{"id":"c8ac7e17-715c-41d2-9bce-18f5ac018a38","acronym":"DESTINY-Breast02","url":"https://clinicaltrials.gov/study/NCT03523585","created_at":"2021-01-18T17:20:52.524Z","updated_at":"2025-02-25T15:07:36.634Z","phase":"Phase 3","brief_title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","source_id_and_acronym":"NCT03523585 - DESTINY-Breast02","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-11-05"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"600fe2c1-8174-4610-9b08-169ca63b195f","acronym":"DESTINY-Breast05","url":"https://clinicaltrials.gov/study/NCT04622319","created_at":"2021-01-19T20:34:44.181Z","updated_at":"2025-02-25T14:59:28.771Z","phase":"Phase 3","brief_title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","source_id_and_acronym":"NCT04622319 - DESTINY-Breast05","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 expression • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 expression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1600","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-10-09"},{"id":"a6aa62c9-583b-4803-a3ef-71521e4f7978","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390427","created_at":"2021-01-18T11:23:47.971Z","updated_at":"2025-02-25T14:00:36.998Z","phase":"Phase 1","brief_title":"Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer","source_id_and_acronym":"NCT02390427","lead_sponsor":"Otto Metzger, MD","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • taselisib (GDC-0032)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 04/20/2015","start_date":" 04/20/2015","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-10-02"},{"id":"b97168d4-4c48-4f7f-a707-018c5065d581","acronym":" DESTINY-Breast01","url":"https://clinicaltrials.gov/study/NCT03248492","created_at":"2021-01-17T17:24:33.001Z","updated_at":"2025-02-25T14:58:16.713Z","phase":"Phase 2","brief_title":"A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)","source_id_and_acronym":"NCT03248492 -  DESTINY-Breast01","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 253","initiation":"Initiation: 08/25/2017","start_date":" 08/25/2017","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 05/06/2024","study_completion_date":" 05/06/2024","last_update_posted":"2024-09-24"},{"id":"686081fb-f277-46dc-b4b1-ec801a5e110d","acronym":"ZEPHIR-02","url":"https://clinicaltrials.gov/study/NCT06595563","created_at":"2025-02-25T18:13:46.825Z","updated_at":"2025-02-25T18:13:46.825Z","phase":"Phase 2","brief_title":"HER2 Molecular Imaging with 89Zr-trastuzumab PET/CT As a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients with Advanced HER2-positive Breast Cancer","source_id_and_acronym":"NCT06595563 - ZEPHIR-02","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-09-13"},{"id":"6c81432a-55dc-40d0-9654-e5d4542eb09f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02326974","created_at":"2021-01-18T11:02:25.914Z","updated_at":"2025-02-25T14:00:34.736Z","phase":"Phase 2","brief_title":"T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA","source_id_and_acronym":"NCT02326974","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 164","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-08-07"},{"id":"75f0b64e-2f38-4d3f-986a-4f0367fd8684","acronym":"BOUQUET","url":"https://clinicaltrials.gov/study/NCT04931342","created_at":"2022-05-03T17:53:37.321Z","updated_at":"2024-07-02T16:34:26.433Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","source_id_and_acronym":"NCT04931342 - BOUQUET","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 10/07/2021","start_date":" 10/07/2021","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-13"},{"id":"4d299e88-5ca6-4c54-98c2-99e458dfc7da","acronym":"DESTINY-Breast03","url":"https://clinicaltrials.gov/study/NCT03529110","created_at":"2021-01-18T17:22:30.182Z","updated_at":"2025-02-25T15:07:37.517Z","phase":"Phase 3","brief_title":"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","source_id_and_acronym":"NCT03529110 - DESTINY-Breast03","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 524","initiation":"Initiation: 08/09/2018","start_date":" 08/09/2018","primary_txt":" Primary completion: 05/21/2021","primary_completion_date":" 05/21/2021","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-12"},{"id":"00bd59ae-be75-47ee-9ac3-1f4257c77d9d","acronym":"HER2CLIMB-02","url":"https://clinicaltrials.gov/study/NCT03975647","created_at":"2021-01-18T19:33:15.474Z","updated_at":"2024-07-02T16:34:27.156Z","phase":"Phase 3","brief_title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT03975647 - HER2CLIMB-02","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 565","initiation":"Initiation: 10/02/2019","start_date":" 10/02/2019","primary_txt":" Primary completion: 06/29/2023","primary_completion_date":" 06/29/2023","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-06-11"},{"id":"edfdc24f-022c-4bdf-b95b-7542ea085b87","acronym":"ATEMPT 2.0","url":"https://clinicaltrials.gov/study/NCT04893109","created_at":"2021-05-19T15:52:52.041Z","updated_at":"2024-07-02T16:34:27.345Z","phase":"Phase 2","brief_title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","source_id_and_acronym":"NCT04893109 - ATEMPT 2.0","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-06-11"},{"id":"ba46c2a2-b8a0-4d55-8e36-8db640687fe6","acronym":"HER2","url":"https://clinicaltrials.gov/study/NCT05650879","created_at":"2022-12-14T14:58:21.956Z","updated_at":"2024-07-02T16:34:37.125Z","phase":"Phase 1","brief_title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05650879 - HER2","lead_sponsor":"Enliven Therapeutics","biomarkers":" BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation","tags":["BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ELVN-002"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-07"}]